ProCE Banner Activity

Evaluation of Quizartinib With Venetoclax and Decitabine Therapy in Patients With Newly Diagnosed or R/R FLT3-Mutated AML

Slideset Download
Conference Coverage
Initial results from this phase I/II trial suggest that the 3-drug regimen is active in heavily pretreated and prior FLT3 inhibitor–exposed patients with relapsed/refractory disease with a CRc rate of 78%.

Released: December 14, 2021

Expiration: December 13, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation